Table 2.
Descriptive baseline characteristics of hospitalized patients with PAH
| Variables | Optum (N = 3116) |
|---|---|
| N/Mean (%/SD) | |
| Age (years) | 68.1 (12.7) |
| Age group (years) | |
| 18–54 | 438 (14.1%) |
| 55–64 | 639 (20.5%) |
| ≥ 65 | 2039 (65.4%) |
| Sex | |
| Male | 994 (31.9%) |
| Female | 2122 (68.1%) |
| US geographic region | |
| Northeast | 328 (10.5%) |
| North Central | 751 (24.1%) |
| South | 1428 (45.8%) |
| West/other | 609 (19.5%) |
| Charlson comorbidity index | |
| Mean CCI | 5.1 (3.0) |
| Comorbiditiesa | |
| Hypertension | 2540 (81.5%) |
| Chronic obstructive pulmonary disease | 1461 (46.9%) |
| Diabetes | 1350 (43.3%) |
| Coronary artery disease/ischemic heart disease | 1271 (40.8%) |
| Renal insufficiency | 1182 (37.9%) |
| Obesity | 819 (26.3%) |
| Lower respiratory disease | 736 (23.6%) |
| Apnea | 580 (18.6%) |
| Depression | 547 (17.6%) |
| Pneumonia | 498 (16.0%) |
| Interstitial lung disease | 479 (15.4%) |
| Sleep disorders | 372 (11.9%) |
| Venous thromboembolism | 338 (10.8%) |
| Liver disease | 306 (9.8%) |
| Congenital heart disease | 211 (6.8%) |
| Idiopathic pulmonary fibrosis | 134 (4.3%) |
| Left heart failure | 108 (3.5%) |
| Baseline PAH medicationsa | |
| Phosphodiesterase (type 5) enzyme inhibitors (PDE-5i) | 1801 (57.8%) |
| Endothelin receptor antagonists (ERAs) | 920 (29.5%) |
| Prostacyclin pathway agents | 337 (10.8%) |
| Soluble guanylate cyclase stimulator (sGCS) | 191 (6.1%) |
| All-cause index hospitalization | |
| Length of stay (days) | 6.6 (8.2) |
aCategories were not mutually exclusive